← 產業報告目錄

Breast Biopsy Devices Market by Product (Needle: Core, FNAB, VAB; Equipment, Wire, Guidance system, Table, Assay kit), Procedure (Needle, Liquid: CTC, CTDNA; Open), Application (Screening, Monitoring), End User (Hospital, Clinic) - Global Forecasts to 2030

出版商 MarketsandMarkets產業別 Medical Devices出版日期 2025-05-23頁數 290報告編號 MD3615

授權報價

Single User Licence$4,950 USD
Multi User Licence$6,650 USD
Corporate User Licence$8,150 USD
Global User Licence$10,000 USD
洽詢購買 申請 Sample

報告摘要

The global market for breast biopsy devices is expected to reach USD 3,261.7 million by 2030 from USD 2,384.1 million in 2025, representing a CAGR of 6.5% during the forecast period. The market is benefiting from a combination of factors, including rising breast cancer rates, increased awareness of the importance of early detection, and the growing preference for minimally invasive diagnostic procedures. Additionally, state and provincial screening programs are significantly improving the rate of screenings among women for potential breast cancer. The biopsy needles segment held the largest share of the market in 2024. Based on type, the breast biopsy devices market is divided into several segments: biopsy needles, guidance systems, biopsy tables, localization wires, assay kits, liquid biopsy instruments, and other devices. Among these, the biopsy needles segment holds a significant share of the market. Biopsy needles are essential tools for diagnosing breast cancer, as they collect tissue samples for histopathological analysis with high accuracy and minimal invasiveness. They can be utilized in core-needle biopsy (CNB), fine-needle aspiration biopsy (FNAB), and vacuum-assisted biopsy (VAB), each designed for specific clinical scenarios and the varying characteristics of the lesions. Biopsy needles are preferred because they provide diagnostic results with less discomfort for the patient and require less time for both the procedure and recovery compared to surgical biopsies. The needle breast biopsy procedure segment accounted for the largest market share in 2024. Based on procedures, the breast biopsy devices market can be broadly categorized into three types: needle breast biopsy, open surgical breast biopsy, and liquid breast biopsy. The growth of the needle breast biopsy segment is driven by several key factors. These include rising breast cancer rates, a greater emphasis on early and accurate diagnosis, and an increasing preference among patients for minimally invasive procedures. Advancements in technology, particularly in image guidance and needle design, have enhanced the accuracy of needle breast biopsies while minimizing discomfort and inconvenience. This has made the procedure more acceptable and feasible for patients. Furthermore, the establishment of breast cancer screening programs, more favorable reimbursement policies, and heightened awareness of women's health issues are also contributing to market growth. Additionally, the preference for outpatient care and the growing interest in cost-effective diagnostic options have led to broader acceptance of needle breast biopsies across various healthcare settings. The liquid biopsy segment is projected to register the highest CAGR during the forecast period. The breast biopsy devices market is primarily categorized into three main techniques: image-guided biopsy, liquid biopsy, and other methods. The liquid biopsy segment is experiencing growth due to the increasing demand for non-invasive, accurate, and real-time cancer diagnostic solutions. Liquid biopsy processes detect circulating tumor cells (CTCs) and circulating tumor DNA (ctDNA) in the blood, making them less invasive than traditional tissue biopsies. This allows for earlier diagnoses, better tracking of treatment responses, and effective monitoring for recurrence or progression of the disease. Several factors are driving the growth of the liquid biopsy market, including the rising incidence of breast cancer, the advancement of precision (or personalized) medicine, and improvements in molecular diagnostic technologies, particularly through next-generation sequencing (NGS) and digital PCR. The increasing clinical utility and routine application of liquid biopsies, along with a growing awareness of their benefits and supportive regulatory policies, are further promoting the global adoption of these technologies. The early cancer screening segment dominated the market in 2024. The breast biopsy market can be broadly categorized based on its applications into four main areas: early cancer screening, therapy selection, treatment monitoring, and recurrence monitoring. Early cancer screening holds the largest market share as it plays a crucial role in reducing mortality rates and improving treatment outcomes by detecting cancer at the earliest and most treatable stage. The rising incidence of cancer globally, particularly among vulnerable and aging populations, has increased the need for effective illness monitoring. Consequently, advancements in technology will serve as a significant driver for early and proactive health monitoring and diagnosis. Asia Pacific is expected to register a significant growth rate in the market during the forecast period. The breast biopsy market is experiencing the highest growth in the Asia Pacific region due to several converging factors. These include an increasing incidence of breast cancer, the development of healthcare infrastructure, and greater awareness of the importance of early cancer detection. Countries such as China, India, and Japan are making significant investments in interventional and diagnostic imaging, which is creating a demand for advanced biopsy technologies. Additionally, government support, improved access to medical care in rural areas, and the expansion of global medical device companies promoting their products in emerging markets are driving this adoption. Furthermore, the region’s large population and rising healthcare spending are key drivers of its double-digit market growth. A breakdown of the primary participants referred to for this report is provided below: • By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%) • By Designation: C-level Executives (27%), Director-level Executives (18%), and Other Designations (55%) • By Region: North America (50%), Europe (20%), Asia Pacific (15%), Latin America (10%), and the Middle East & Africa (5%) Prominent players in this market are Hologic Inc. (US), Danaher Corporation (US), Argon Medical Devices (US), Merit Medical Systems (US), Menarini-Silicon Biosystems (Italy), Varian Medical Systems, Inc. (Germany), Planmed Oy (Finland), Sterylab S.R.L (Italy), Biocept, Inc. (US), Bio-Rad Laboratories, Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN (Germany), and Exact Sciences Corporation (US). Research Coverage • The report studies the breast biopsy devices market by product, procedure, application, end user, and region. • The report analyzes factors affecting market growth (drivers, restraints, opportunities, and challenges). • The report evaluates the market opportunities and challenges for stakeholders and details the competitive landscape for market leaders. • The report studies micromarkets with respect to their growth trends, prospects, and contributions to the global breast biopsy devices market. • The report forecasts the revenue of market segments with respect to five major regions. Key Benefits of Buying the Report: The report is designed to assist both new entrants and established market leaders, as well as smaller companies in the breast biopsy devices sector, in making informed investment decisions. It provides comprehensive data that supports risk evaluation and validated investment strategies. The report features detailed market segmentation based on end users and regional aspects, enabling you to focus on specific segments. Additionally, it offers thorough coverage and analysis of trends, challenges, growth opportunities, and future prospects, ensuring that your decisions are well-informed and considerate of all relevant factors. The report provides insights into the following pointers: • Analysis of key drivers (ongoing innovations in biopsy needle designs and liquid biopsy technologies), restraints (high costs associated with advanced biopsy equipment and imaging technologies and stringent regulatory approval procedures), opportunities (technological advancements in imaging technology), and challenges (accuracy and reliability of certain biopsy procedures), influencing the growth of the breast biopsy devices market. • Product Development/Innovation: Detailed insights into upcoming technologies, R&D activities, and new product & service launches in the breast biopsy devices market. • Market Diversification: Exhaustive information about untapped geographies, new products, recent developments, and investments in the breast biopsy devices market. • Market Development: Comprehensive information about lucrative markets—the report analyzes the breast biopsy devices market across varied regions. • Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of leading players such as Hologic Inc. (US), Danaher Corporation (US), Argon Medical Devices (US), Merit Medical Systems (US), Menarini-Silicon Biosystems (Italy), Varian Medical Systems, Inc. (Germany), Planmed Oy (Finland), Sterylab S.R.L (Italy), QIAGEN (Germany), and Biocept, Inc. (US), among others
目錄 Table of Contents
1 INTRODUCTION 26 1.1 STUDY OBJECTIVES 26 1.2 MARKET DEFINITION 26 1.3 STUDY SCOPE 27 1.3.1 MARKETS COVERED & REGIONAL SCOPE 27 1.3.2 INCLUSIONS & EXCLUSIONS 28 1.3.3 YEARS CONSIDERED 28 1.4 CURRENCY CONSIDERED 28 1.5 STUDY LIMITATIONS 29 1.6 STAKEHOLDERS 29 1.7 SUMMARY OF CHANGES 29 2 RESEARCH METHODOLOGY 31 2.1 RESEARCH DATA 31 2.1.1 SECONDARY DATA 32 2.1.1.1 Key sources of secondary data 32 2.1.1.2 Objectives of secondary research 33 2.1.1.3 Key data from secondary sources 34 2.1.2 PRIMARY DATA 35 2.1.2.1 Key primary sources 35 2.1.2.2 Key objectives of primary research 35 2.1.2.3 Key industry insights 36 2.2 MARKET SIZE ESTIMATION 37 2.2.1 BOTTOM-UP APPROACH (REVENUE SHARE ANALYSIS) 39 2.2.1.1 Company revenue estimation approach 39 2.2.1.2 Customer-based market estimation 40 2.2.2 TOP-DOWN APPROACH 40 2.3 DATA TRIANGULATION 43 2.4 MARKET SHARE ASSESSMENT 44 2.5 STUDY ASSUMPTIONS 44 2.5.1 MARKET ASSUMPTIONS 44 2.5.2 GROWTH RATE ASSUMPTIONS 44 2.6 RESEARCH LIMITATIONS 45 2.7 RISK ANALYSIS 45 3 EXECUTIVE SUMMARY 46   4 PREMIUM INSIGHTS 50 4.1 BREAST BIOPSY DEVICES MARKET OVERVIEW 50 4.2 BREAST BIOPSY DEVICES MARKET, BY REGION, 2025 VS. 2030 (USD MILLION) 51 4.3 EUROPE: BREAST BIOPSY DEVICES MARKET, BY REGION AND APPLICATION, 2024 52 4.4 GEOGRAPHIC SNAPSHOT OF BREAST BIOPSY DEVICES MARKET 53 5 MARKET OVERVIEW 54 5.1 INTRODUCTION 54 5.2 MARKET DYNAMICS 54 5.2.1 DRIVERS 55 5.2.1.1 Growing incidence of breast cancer 55 5.2.1.2 Expansion of private diagnostic chains and imaging centers 55 5.2.1.3 Increasing demand for minimally invasive and non-invasive procedures 56 5.2.1.4 Growing awareness regarding early detection of breast cancer 56 5.2.1.5 Improved reimbursement scenario 57 5.2.2 RESTRAINTS 58 5.2.2.1 High cost of liquid biopsy tests 58 5.2.2.2 Stringent regulatory approval procedures 59 5.2.3 OPPORTUNITIES 59 5.2.3.1 Technological advancements 59 5.2.3.2 Growing collaboration and financial support from public and private sectors 60 5.2.4 CHALLENGES 61 5.2.4.1 Shortage of skilled professionals 61 5.3 REGULATORY ANALYSIS 61 5.3.1 REGULATORY BODIES, GOVERNMENT AGENCIES AND OTHER ORGANIZATIONS 62 5.3.2 REGULATORY LANDSCAPE 63 5.3.2.1 North America 64 5.3.2.1.1 US 64 5.3.2.1.2 Canada 65 5.3.2.2 Europe 65 5.3.2.3 Asia Pacific 66 5.3.2.3.1 Japan 66 5.3.2.3.2 China 67 5.3.2.3.3 India 68 5.4 VALUE CHAIN ANALYSIS 68 5.5 SUPPLY CHAIN ANALYSIS 70 5.5.1 PROMINENT COMPANIES 70 5.5.2 SMALL & MEDIUM-SIZED ENTERPRISES 70 5.5.3 END USERS 70 5.6 ECOSYSTEM ANALYSIS 71 5.7 TECHNOLOGY ANALYSIS 72 5.7.1 KEY TECHNOLOGIES 72 5.7.1.1 Ultrasound 72 5.7.1.2 Mammography-guided stereotactic biopsy 73 5.7.1.3 MRI 73 5.7.1.4 Contrast-enhanced mammography (CEM) guidance 73 5.7.2 COMPLEMENTARY TECHNOLOGIES 73 5.7.2.1 Gamma-guided biopsy systems 73 5.7.2.2 Molecular breast imaging (MBI)-guided biopsy 74 5.7.3 ADJACENT TECHNOLOGIES 74 5.7.3.1 Surgical oncology technologies 74 5.7.3.2 Cryoablation and other minimally invasive ablation technologies 74 5.8 TRADE ANALYSIS 75 5.8.1 IMPORT DATA 75 5.8.2 EXPORT DATA 75 5.9 PATENT ANALYSIS 76 5.10 PORTER’S FIVE FORCES ANALYSIS 77 5.10.1 THREAT OF NEW ENTRANTS 78 5.10.2 THREAT OF SUBSTITUTES 78 5.10.3 BARGAINING POWER OF SUPPLIERS 78 5.10.4 BARGAINING POWER OF BUYERS 78 5.10.5 INTENSITY OF COMPETITIVE RIVALRY 78 5.11 PRICING ANALYSIS 79 5.11.1 AVERAGE SELLING PRICE TREND OF BREAST BIOPSY DEVICES, BY REGION 79 5.11.2 AVERAGE SELLING PRICE OF BREAST BIOPSY DEVICES, BY APPLICATION 81 5.12 CASE STUDY ANALYSIS 82 5.12.1 CASE STUDY 1: PET-GUIDED BREAST BIOPSY 82 5.12.2 CASE STUDY 2: EARLY-STAGE BREAST CANCER AMID COVID PANDEMIC 82 5.12.3 CASE STUDY 3: SAMPLING MULTIPLE SMALL LESIONS IN DENSE BREAST TISSUE 83 5.13 KEY CONFERENCES & EVENTS, 2025–2026 83 5.14 KEY STAKEHOLDERS & BUYING CRITERIA 84 5.14.1 KEY STAKEHOLDERS 84 5.14.2 BUYING CRITERIA 85 5.15 IMPACT OF 2025 US TARIFF ON BREAST BIOPSY DEVICES MARKET 86 5.15.1 INTRODUCTION 86 5.15.2 KEY TARIFF RATES 86 5.15.3 PRICE IMPACT ANALYSIS 87   5.15.4 IMPACT ON COUNTRY/REGION 87 5.15.4.1 US 87 5.15.4.2 Europe 88 5.15.4.3 Asia Pacific 88 5.15.5 IMPACT ON END-USE INDUSTRIES 88 5.16 IMPACT OF GENERATIVE AI/AI ON BREAST BIOPSY DEVICES MARKET 89 5.17 INVESTMENT & FUNDING SCENARIO 90 6 BREAST BIOPSY DEVICES MARKET, BY PROCEDURE 92 6.1 INTRODUCTION 93 6.2 NEEDLE BREAST BIOPSY 93 6.2.1 CORE NEEDLE BIOPSY 94 6.2.1.1 Procedural advantages of guidance system-based biopsy to drive revenue growth 94 6.2.2 VACUUM-ASSISTED BIOPSY (VAB) 95 6.2.2.1 High diagnostic specificity and accuracy of technique to boost demand 95 6.2.3 FINE NEEDLE ASPIRATION BIOPSY (FNAB) 96 6.2.3.1 Drawbacks associated with procedure to limit market growth 96 6.3 OPEN SURGICAL BREAST BIOPSY 97 6.3.1 EXCISIONAL BIOPSY 98 6.3.1.1 Risk of post-operative complications to hinder market growth 98 6.3.2 INCISIONAL BIOPSY 98 6.3.2.1 Longer recovery period associated with incisional biopsy to restrict growth 98 6.4 LIQUID BREAST BIOPSY 99 6.4.1 CIRCULATING TUMOR CELLS 100 6.4.1.1 Ability to provide important information on molecular properties of breast tumors to boost market 100 6.4.2 CIRCULATING TUMOR DNA (CTDNA) 100 6.4.2.1 Low concentrations of ctDNA to make screening for clinically relevant mutations challenging 100 6.4.3 OTHER BIOMARKERS 101 7 BREAST BIOPSY DEVICES MARKET, BY PRODUCT 103 7.1 INTRODUCTION 104 7.2 BIOPSY NEEDLES 105 7.2.1 CORE NEEDLES 106 7.2.1.1 Early detection through core needle biopsy to boost growth 106 7.2.2 FINE ASPIRATION NEEDLES 107 7.2.2.1 Accurate clinical decisions for early cancer diagnosis to drive demand for fine aspiration needles 107   7.2.3 VACUUM-ASSISTED BIOPSY NEEDLES 108 7.2.3.1 Enhanced accuracy with vacuum-assisted tissue sampling to drive adoption 108 7.3 BIOPSY EQUIPMENT 108 7.3.1 CORE BIOPSY EQUIPMENT 110 7.3.1.1 Ability to streamline breast diagnosis with core biopsy technology to boost demand 110 7.3.2 VACUUM-ASSISTED BIOPSY EQUIPMENT 111 7.3.2.1 Advantages of VAB in breast biopsy to drive market growth 111 7.4 GUIDANCE SYSTEMS 111 7.4.1 MAMMOGRAPHY-GUIDED STEREOTACTIC BIOPSY 112 7.4.1.1 Advantages of technique to boost adoption in coming years 112 7.4.2 ULTRASOUND-GUIDED BIOPSY 113 7.4.2.1 Ability to create fine-grained pictures of breasts to drive growth 113 7.4.3 MRI-GUIDED BIOPSY 114 7.4.3.1 High cost and low specificity to affect demand 114 7.5 BIOPSY TABLES 114 7.5.1 GROWING USE OF BIOPSY TABLES TO PERFORM STEREOTACTIC BIOPSY PROCEDURES TO FAVOR MARKET GROWTH 114 7.6 ASSAY KITS 115 7.6.1 PRODUCT APPROVALS AND LAUNCHES TO DRIVE SEGMENTAL GROWTH 115 7.7 LIQUID BIOPSY INSTRUMENTS 116 7.7.1 ONGOING RESEARCH AND CLINICAL TRIALS TO DELIVER NOVEL SOLUTIONS IN MARKET 116 7.8 LOCALIZATION WIRES 117 7.8.1 WIDE USAGE OF LOCALIZATION WIRES TO LOCATE BREAST ABNORMALITIES AND LUMPS TO BOOST MARKET 117 7.9 OTHER PRODUCTS 118 8 BREAST BIOPSY MARKET, BY APPLICATION 119 8.1 INTRODUCTION 120 8.2 EARLY CANCER SCREENING 120 8.2.1 GROWING AWARENESS ABOUT EARLY CANCER DETECTION TO DRIVE SEGMENT GROWTH 120 8.3 THERAPY SELECTION 121 8.3.1 ABILITY OF PERSONALIZED THERAPY SELECTION TO ENHANCE TREATMENT EFFICACY TO DRIVE DEMAND 121 8.4 TREATMENT MONITORING 122 8.4.1 GROWING POPULARITY OF REAL-TIME TREATMENT MONITORING TO BOOST MARKET 122 8.5 RECURRENCE MONITORING 122 8.5.1 UNMET CLINICAL NEEDS TO CREATE OPPORTUNITIES FOR PLAYERS IN MARKET 122   9 BREAST BIOPSY DEVICES MARKET, BY END USER 124 9.1 INTRODUCTION 125 9.2 HOSPITALS & CLINICS 125 9.2.1 RISING DEMAND FOR QUICK AND ACCURATE DIAGNOSIS TO BOOST MARKET 125 9.3 IMAGING CLINICS & DIAGNOSTIC CENTERS 126 9.3.1 RISING NUMBER OF PRIVATE IMAGING CENTERS TO CONTRIBUTE TO MARKET GROWTH 126 9.4 BREAST CARE CENTERS 127 9.4.1 INCREASING POPULARITY OF BREAST CARE CENTERS IN DEVELOPED COUNTRIES TO BOOST MARKET 127 10 BREAST BIOPSY DEVICES MARKET, BY REGION 129 10.1 INTRODUCTION 130 10.2 NORTH AMERICA 132 10.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 132 10.2.2 US 137 10.2.2.1 US to dominate North America breast biopsy devices market during forecast period 137 10.2.3 CANADA 140 10.2.3.1 Surge in incidence of breast cancer and favorable government guidelines to support market growth 140 10.3 EUROPE 142 10.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 143 10.3.2 GERMANY 147 10.3.2.1 Favorable changes in reimbursement scenario to fuel adoption of technologically advanced products in Germany 147 10.3.3 UK 149 10.3.3.1 Initiatives by public & private organizations to increase awareness about breast cancer to drive growth 149 10.3.4 FRANCE 152 10.3.4.1 Rising geriatric population to support market growth 152 10.3.5 ITALY 154 10.3.5.1 Evolving regulatory scenario for breast biopsy to boost market 154 10.3.6 SPAIN 157 10.3.6.1 Increased funding scenario to propel market growth 157 10.3.7 REST OF EUROPE 159 10.4 ASIA PACIFIC 161 10.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 162 10.4.2 CHINA 167 10.4.2.1 Increasing patient pool and government initiatives for healthcare development to fuel market growth 167 10.4.3 JAPAN 170 10.4.3.1 Presence of universal healthcare reimbursement scenario and rising breast cancer cases 170 10.4.4 INDIA 172 10.4.4.1 Government initiatives to improve female health to drive market growth in India 172 10.4.5 AUSTRALIA 175 10.4.5.1 Rising research investments and awareness campaigns to support market growth 175 10.4.6 SOUTH KOREA 177 10.4.6.1 Rising R&D and promising clinical trials in country to positively impact market growth 177 10.4.7 REST OF ASIA PACIFIC 179 10.5 LATIN AMERICA 181 10.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 182 10.5.2 BRAZIL 186 10.5.2.1 Key market in Latin America owing to modernization of healthcare facilities 186 10.5.3 MEXICO 188 10.5.3.1 Availability of advanced care and increasing awareness programs to fuel market growth 188 10.5.4 REST OF LATIN AMERICA 190 10.6 MIDDLE EAST & AFRICA 192 10.6.1 IMPROVING HEALTHCARE INFRASTRUCTURE AND INCREASING PUBLIC–PRIVATE INVESTMENTS TO DRIVE MARKET GROWTH IN MEA REGION 192 10.6.2 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 193 10.6.3 GCC COUNTRIES 197 10.6.3.1 Growing healthcare infrastructure to fuel market growth 197 10.6.4 REST OF MIDDLE EAST & AFRICA 199 11 COMPETITIVE LANDSCAPE 202 11.1 INTRODUCTION 202 11.2 KEY PLAYER STRATEGY/RIGHT TO WIN 202 11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS 203 11.3 REVENUE ANALYSIS, 2020–2024 204 11.4 MARKET SHARE ANALYSIS, 2024 205 11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS (2024) 208 11.5.1 STARS 208 11.5.2 EMERGING LEADERS 208 11.5.3 PERVASIVE PLAYERS 208 11.5.4 PARTICIPANTS 208 11.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2023 210 11.5.5.1 Company footprint 210 11.5.5.2 Region footprint 211 11.5.5.3 Product footprint 212   11.5.5.4 Procedure footprint 213 11.5.5.5 Application footprint 214 11.5.5.6 End-user footprint 215 11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES (2024) 216 11.6.1 PROGRESSIVE COMPANIES 216 11.6.2 RESPONSIVE COMPANIES 216 11.6.3 DYNAMIC COMPANIES 216 11.6.4 STARTING BLOCKS 216 11.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 218 11.6.5.1 Detailed list of key startups/SMEs 218 11.6.5.2 Competitive benchmarking of startup/SME players, by region 218 11.6.5.3 Competitive benchmarking of startup/SME players, product 219 11.7 COMPANY VALUATION & FINANCIAL METRICS 220 11.7.1 FINANCIAL METRICS 220 11.7.2 COMPANY VALUATION 220 11.8 BRAND/PRODUCT COMPARISON 221 11.9 COMPETITIVE SCENARIO 222 11.9.1 THIS SEGMENT INCLUDES THE GROWTH STRATEGIES ADOPTED BY MAJOR PLAYERS IN THE BREAST BIOPSY DEVICES MARKET BETWEEN JANUARY 2020 AND MAY 2025. 222 11.9.2 PRODUCT LAUNCHES & APPROVALS 222 11.9.3 DEALS 223 12 COMPANY PROFILES 224 12.1 KEY PLAYERS 224 12.1.1 HOLOGIC, INC. 224 12.1.1.1 Business overview 224 12.1.1.2 Products offered 225 12.1.1.2.1 Deals 226 12.1.1.3 MnM view 227 12.1.1.3.1 Key strengths 227 12.1.1.3.2 Strategic choices 227 12.1.1.3.3 Weaknesses & competitive threats 227 12.1.2 DANAHER CORPORATION 228 12.1.2.1 Business overview 228 12.1.2.2 Products offered 229 12.1.2.3 Recent developments 230 12.1.2.3.1 Product launches & approvals 230 12.1.2.3.2 Deals 231 12.1.2.4 MnM view 231 12.1.2.4.1 Key strengths 231 12.1.2.4.2 Strategic choices 232 12.1.2.4.3 Weaknesses & competitive threats 232 12.1.3 BECTON, DICKINSON AND COMPANY 233 12.1.3.1 Business overview 233 12.1.3.2 Products offered 234 12.1.3.3 MnM View 235 12.1.3.3.1 Key strengths 235 12.1.3.3.2 Strategic choices 235 12.1.3.3.3 Weaknesses & competitive threats 235 12.1.4 ARGON MEDICAL 236 12.1.4.1 Business overview 236 12.1.4.2 Products offered 236 12.1.4.3 Recent developments 237 12.1.4.3.1 Product launches & approvals 237 12.1.4.3.2 Deals 237 12.1.4.4 MnM view 238 12.1.4.4.1 Key strengths 238 12.1.4.4.2 Strategic choices 238 12.1.4.4.3 Weaknesses & competitive threats 238 12.1.5 QIAGEN 239 12.1.5.1 Business overview 239 12.1.5.2 Products offered 240 12.1.5.3 Recent developments 241 12.1.5.3.1 Deals 241 12.1.5.4 MnM view 241 12.1.5.4.1 Key strengths 241 12.1.5.4.2 Strategic choices 241 12.1.5.4.3 Weaknesses & competitive threats 241 12.1.6 MERIT MEDICAL SYSTEMS 242 12.1.6.1 Business overview 242 12.1.6.2 Products offered 243 12.1.6.3 Recent developments 244 12.1.6.3.1 Product launches & approvals 244 12.1.6.3.2 Deals 245 12.1.7 MENARINI SILICON BIOSYSTEMS SPA 246 12.1.7.1 Business overview 246 12.1.7.2 Products offered 246 12.1.7.3 Recent developments 247 12.1.7.3.1 Product launches & approvals 247 12.1.7.3.2 Deals 247 12.1.8 GUARDANT HEALTH, INC. 248 12.1.8.1 Business overview 248 12.1.8.2 Products offered 249   12.1.8.3 Recent developments 250 12.1.8.3.1 Product launches & approvals 250 12.1.8.3.2 Deals 250 12.1.8.3.3 Other developments 251 12.1.9 NEOGENOMICS LABORATORIES, INC. 252 12.1.9.1 Business overview 252 12.1.9.2 Products offered 253 12.1.9.3 Recent developments 253 12.1.9.3.1 Product launches & approvals 253 12.1.9.3.2 Deals 254 12.1.10 STERYLAB S.R.L 255 12.1.10.1 Business overview 255 12.1.10.2 Products offered 255 12.1.11 BIOCEPT, INC. 256 12.1.11.1 Business overview 256 12.1.11.2 Products offered 256 12.1.12 BIO-RAD LABORATORIES, INC. 258 12.1.12.1 Business overview 258 12.1.12.2 Products offered 259 12.1.12.3 Recent developments 260 12.1.12.3.1 Product launches & approvals 260 12.1.13 F. HOFFMANN-LA ROCHE LTD. 261 12.1.13.1 Business overview 261 12.1.13.2 Products offered 262 12.1.14 EXACT SCIENCES CORPORATION 263 12.1.14.1 Business overview 263 12.1.14.2 Products offered 264 12.1.14.3 Recent developments 265 12.1.14.3.1 Deals 265 12.1.15 SYSMEX INOSTICS (A SUBSIDIARY OF SYSMEX CORPORATION) 266 12.1.15.1 Business overview 266 12.1.15.2 Products offered 267 12.1.15.3 Recent developments 268 12.1.15.3.1 Deals 268 12.1.16 THERMO FISHER SCIENTIFIC 269 12.1.16.1 Business overview 269 12.1.16.2 Products offered 270 12.1.16.3 Recent developments 271 12.1.16.3.1 Deals 271 12.1.17 FUJIFILM HOLDINGS CORPORATION 272 12.1.17.1 Business overview 272 12.1.17.2 Products offered 273 12.2 OTHER PLAYERS 274 12.2.1 CARDIFF ONCOLOGY INC. 274 12.2.2 MYRIAD GENETICS, INC. 275 12.2.3 ILLUMINA, INC. 276 12.2.4 FLUXION BIOSCIENCES, INC. 277 12.2.5 INRAD, INC. 278 12.2.6 IZI MEDICAL PRODUCTS 279 12.2.7 REMINGTON MEDICAL INC. 280 12.2.8 CP MEDICAL 281 13 APPENDIX 282 13.1 DISCUSSION GUIDE 282 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 286 13.3 CUSTOMIZATION OPTIONS 288 13.4 RELATED REPORTS 288 13.5 AUTHOR DETAILS 289
圖表清單 List of Tables & Figures
TABLE 1 BREAST BIOPSY DEVICES MARKET: STUDY ASSUMPTIONS 44 TABLE 2 BREAST BIOPSY DEVICES MARKET: RISK ANALYSIS 45 TABLE 3 MEDICARE REIMBURSEMENT FOR BREAST BIOPSY 57 TABLE 4 COST AND UTILITY MODEL INPUTS (2022) 58 TABLE 5 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 62 TABLE 6 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 62 TABLE 7 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 62 TABLE 8 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 63 TABLE 9 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 63 TABLE 10 US FDA: MEDICAL DEVICE CLASSIFICATION 64 TABLE 11 US: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 65 TABLE 12 CANADA: MEDICAL DEVICE REGULATORY APPROVAL PROCESS 65 TABLE 13 JAPAN: MEDICAL DEVICE CLASSIFICATION UNDER PMDA 66 TABLE 14 CHINA: CLASSIFICATION OF MEDICAL DEVICES 67 TABLE 15 BREAST BIOPSY DEVICES MARKET: ROLE IN ECOSYSTEM 72 TABLE 16 IMPORT DATA FOR NEEDLES, CATHETERS, AND CANNULAE (HS CODE 901839), BY COUNTRY, 2020–2024 (USD THOUSAND) 75 TABLE 17 EXPORT DATA FOR BREAST BIOPSY DEVICES (HS CODE 901839), BY COUNTRY, 2020–2024 (USD THOUSAND) 75 TABLE 18 BREAST BIOPSY DEVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 77 TABLE 19 INDICATIVE SELLING PRICE TREND OF BREAST BIOPSY DEVICES, BY REGION, 2022–2024 (USD) 80 TABLE 20 AVERAGE SELLING PRICE OF BREAST BIOPSY DEVICES, BY KEY PLAYER, 2024 (USD) 81 TABLE 21 BREAST BIOPSY DEVICES MARKET: LIST OF MAJOR CONFERENCES & EVENTS 83 TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BREAST BIOPSY DEVICES, BY TOP THREE END USERS 85 TABLE 23 KEY BUYING CRITERIA FOR TOP THREE END USERS OF BREAST BIOPSY DEVICES 85 TABLE 24 US-ADJUSTED RECIPROCAL TARIFF RATES 86 TABLE 25 BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 93 TABLE 26 NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 94 TABLE 27 CORE NEEDLE BIOPSY DEVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 95 TABLE 28 VACUUM-ASSISTED BIOPSY DEVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 96 TABLE 29 FINE NEEDLE ASPIRATION BIOPSY DEVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 97 TABLE 30 OPEN SURGICAL BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 97 TABLE 31 EXCISIONAL BIOPSY DEVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 98 TABLE 32 INCISIONAL BIOPSY DEVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 99 TABLE 33 LIQUID BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 99 TABLE 34 LIQUID BREAST BIOPSY DEVICES MARKET FOR CIRCULATING TUMOR CELLS, BY REGION, 2023–2030 (USD MILLION) 100 TABLE 35 LIQUID BREAST BIOPSY DEVICES MARKET FOR CIRCULATING TUMOR DNA, BY REGION, 2023–2030 (USD MILLION) 101 TABLE 36 LIQUID BREAST BIOPSY DEVICES MARKET FOR OTHER BIOMARKERS, BY REGION, 2023–2030 (USD MILLION) 102 TABLE 37 BREAST BIOPSY DEVICES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 104 TABLE 38 BREAST BIOPSY DEVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 104 TABLE 39 BREAST BIOPSY DEVICES MARKET FOR BIOPSY NEEDLES, BY REGION, 2023–2030 (USD MILLION) 105 TABLE 40 BREAST BIOPSY DEVICES MARKET FOR BIOPSY NEEDLES, BY TYPE, 2023–2030 (USD MILLION) 106 TABLE 41 BREAST BIOPSY DEVICES MARKET FOR CORE NEEDLES, BY REGION, 2023–2030 (USD MILLION) 106 TABLE 42 BREAST BIOPSY DEVICES MARKET FOR FINE ASPIRATION NEEDLES, BY REGION, 2023–2030 (USD MILLION) 107 TABLE 43 BREAST BIOPSY DEVICES MARKET FOR VACUUM-ASSISTED NEEDLES, BY REGION, 2023–2030 (USD MILLION) 108 TABLE 44 BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY REGION, 2023–2030 (USD MILLION) 109 TABLE 45 BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 109 TABLE 46 BREAST BIOPSY DEVICES MARKET FOR CORE BIOPSY EQUIPMENT, BY REGION, 2023–2030 (USD MILLION) 110 TABLE 47 BREAST BIOPSY DEVICES MARKET FOR VACUUM-ASSISTED BIOPSY EQUIPMENT, BY REGION, 2023–2030 (USD MILLION) 111 TABLE 48 BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY REGION, 2023–2030 (USD MILLION) 112 TABLE 49 BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 112 TABLE 50 BREAST BIOPSY DEVICES MARKET FOR MAMMOGRAPHY-GUIDED STEREOTACTIC BIOPSY, BY REGION, 2023–2030 (USD MILLION) 113 TABLE 51 BREAST BIOPSY DEVICES MARKET FOR ULTRASOUND-GUIDED BIOPSY, BY REGION, 2023–2030 (USD MILLION) 113 TABLE 52 BREAST BIOPSY DEVICES MARKET FOR MRI-GUIDED BIOPSY, BY REGION, 2023–2030 (USD MILLION) 114 TABLE 53 BREAST BIOPSY DEVICES MARKET FOR BIOPSY TABLES, BY REGION, 2023–2030 (USD MILLION) 115 TABLE 54 BREAST BIOPSY DEVICES MARKET FOR ASSAY KITS, BY REGION, 2023–2030 (USD MILLION) 116 TABLE 55 BREAST BIOPSY DEVICES MARKET FOR LIQUID BIOPSY INSTRUMENTS, BY REGION, 2023–2030 (USD MILLION) 117 TABLE 56 BREAST BIOPSY DEVICES MARKET FOR LOCALIZATION WIRES, BY REGION, 2023–2030 (USD MILLION) 118 TABLE 57 BREAST BIOPSY DEVICES MARKET FOR OTHER PRODUCTS, BY REGION, 2023–2030 (USD MILLION) 118 TABLE 58 BREAST BIOPSY DEVICES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 120 TABLE 59 BREAST BIOPSY DEVICES MARKET FOR EARLY CANCER SCREENING, BY REGION, 2023–2030 (USD MILLION) 121 TABLE 60 BREAST BIOPSY DEVICES MARKET FOR THERAPY SELECTION, BY REGION, 2023–2030 (USD MILLION) 121 TABLE 61 BREAST BIOPSY DEVICES MARKET FOR TREATMENT MONITORING, BY REGION, 2023–2030 (USD MILLION) 122 TABLE 62 BREAST BIOPSY DEVICES MARKET FOR RECURRENCE MONITORING, BY REGION, 2023–2030 (USD MILLION) 123 TABLE 63 BREAST BIOPSY DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 125 TABLE 64 BREAST BIOPSY DEVICES MARKET FOR HOSPITALS & CLINICS, BY REGION, 2023–2030 (USD MILLION) 126 TABLE 65 BREAST BIOPSY DEVICES MARKET FOR IMAGING CLINICS & DIAGNOSTIC CENTERS, BY REGION, 2023–2030 (USD MILLION) 127 TABLE 66 BREAST BIOPSY DEVICES MARKET FOR BREAST CARE CENTERS, BY REGION, 2023–2030 (USD MILLION) 128 TABLE 67 BREAST BIOPSY DEVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 130 TABLE 68 TOTAL NUMBER OF BREAST BIOPSY PROCEDURES BY REGION, 2024 131 TABLE 69 VACCUM ASSISTED BIOPSY NEEDLES MARKET, REGION, 2023–2030 (USD MILLION) 131 TABLE 70 NA BREAST BIOPSY DEVICES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 131 TABLE 71 NORTH AMERICA: MACROINDICATORS 132 TABLE 72 NORTH AMERICA: BREAST BIOPSY DEVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 134 TABLE 73 NORTH AMERICA: BREAST BIOPSY DEVICES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 134 TABLE 74 NORTH AMERICA: BREAST BIOPSY DEVICES MARKET, BY PROCEDURE, 2023–2030 (USD MILLION) 135 TABLE 75 NORTH AMERICA: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 135 TABLE 76 NORTH AMERICA: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 136 TABLE 77 NORTH AMERICA: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 136 TABLE 78 NORTH AMERICA: BREAST BIOPSY DEVICES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 137 TABLE 79 NORTH AMERICA: BREAST BIOPSY DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 137 TABLE 80 US: BREAST BIOPSY DEVICES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 138 TABLE 81 US: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 139 TABLE 82 US: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 139 TABLE 83 US: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 140 TABLE 84 CANADA: BREAST BIOPSY DEVICES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 141 TABLE 85 CANDA: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 141 TABLE 86 CANADA: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 142 TABLE 87 CANADA: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 142 TABLE 88 EUROPE: MACROINDICATORS 143 TABLE 89 EUROPE: BREAST BIOPSY DEVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 143 TABLE 90 EUROPE: BREAST BIOPSY DEVICES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 144 TABLE 91 EUROPE: BREAST BIOPSY DEVICES MARKET, BY PROCEDURE, 2023–2030 (USD MILLION) 144 TABLE 92 EUROPE: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 145 TABLE 93 EUROPE: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 145 TABLE 94 EUROPE: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 146 TABLE 95 EUROPE: BREAST BIOPSY DEVICES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 146 TABLE 96 EUROPE: BREAST BIOPSY DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 147 TABLE 97 GERMANY: BREAST BIOPSY DEVICES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 148 TABLE 98 GERMANY: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 148 TABLE 99 GERMANY: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 149 TABLE 100 GERMANY: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 149 TABLE 101 UK: BREAST BIOPSY DEVICES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 150 TABLE 102 UK: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 151 TABLE 103 UK: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 151 TABLE 104 UK: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 152 TABLE 105 FRANCE: BREAST BIOPSY DEVICES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 153 TABLE 106 FRANCE: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 153 TABLE 107 FRANCE: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 154 TABLE 108 FRANCE: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 154 TABLE 109 ITALY: BREAST BIOPSY DEVICES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 155 TABLE 110 ITALY: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 156 TABLE 111 ITALY BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 156 TABLE 112 ITALY: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 157 TABLE 113 SPAIN: BREAST BIOPSY DEVICES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 158 TABLE 114 SPAIN: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 158 TABLE 115 SPAIN: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 159 TABLE 116 SPAIN: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 159 TABLE 117 REST OF EUROPE: BREAST BIOPSY DEVICES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 160 TABLE 118 REST OF EUROPE: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 160 TABLE 119 REST OF EUROPE: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 161 TABLE 120 REST OF EUROPE: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 161 TABLE 121 ASIA PACIFIC: MACROINDICATORS 162 TABLE 122 ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 164 TABLE 123 ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 164 TABLE 124 ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET, BY PROCEDURE, 2023–2030 (USD MILLION) 165 TABLE 125 ASIA PACIFIC: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 165 TABLE 126 ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 166 TABLE 127 ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 166 TABLE 128 ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 167 TABLE 129 ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 167 TABLE 130 CHINA: BREAST BIOPSY DEVICES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 168 TABLE 131 CHINA: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 169 TABLE 132 CHINA: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 169 TABLE 133 CHINA: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 170 TABLE 134 JAPAN: BREAST BIOPSY DEVICES MARKET, BY PRODUCT, 2023–2030 171 TABLE 135 JAPAN: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 171 TABLE 136 JAPAN: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 172 TABLE 137 JAPAN: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 172 TABLE 138 INDIA: BREAST BIOPSY DEVICES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 173 TABLE 139 INDIA: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 174 TABLE 140 INDIA: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 174 TABLE 141 INDIA: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 175 TABLE 142 AUSTRALIA: BREAST BIOPSY DEVICES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 176 TABLE 143 AUSTRALIA: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 176 TABLE 144 AUSTRALIA: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 177 TABLE 145 AUSTRALIA: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 177 TABLE 146 SOUTH KOREA: BREAST BIOPSY DEVICES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 178 TABLE 147 SOUTH KOREA: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 178 TABLE 148 SOUTH KOREA: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 179 TABLE 149 SOUTH KOREA: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 179 TABLE 150 REST OF ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 180 TABLE 151 REST OF ASIA PACIFIC: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 180 TABLE 152 REST OF ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 181 TABLE 153 REST OF ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 181 TABLE 154 LATIN AMERICA: MACROINDICATORS 182 TABLE 155 LATIN AMERICA: BREAST BIOPSY DEVICES MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 182 TABLE 156 LATIN AMERICA: BREAST BIOPSY DEVICES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 183 TABLE 157 LATIN AMERICA: BREAST BIOPSY DEVICES MARKET, BY PROCEDURE, 2023–2030 (USD MILLION) 183 TABLE 158 LATIN AMERICA: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 184 TABLE 159 LATIN AMERICA: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 184 TABLE 160 LATIN AMERICA: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 185 TABLE 161 LATIN AMERICA: BREAST BIOPSY DEVICES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 185 TABLE 162 LATIN AMERICA: BREAST BIOPSY DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 186 TABLE 163 BRAZIL: BREAST BIOPSY DEVICES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 187 TABLE 164 BRAZIL: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 187 TABLE 165 BRAZIL: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 188 TABLE 166 BRAZIL: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 188 TABLE 167 MEXICO: BREAST BIOPSY DEVICES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 189 TABLE 168 MEXICO: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 189 TABLE 169 MEXICO: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 190 TABLE 170 MEXICO: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 190 TABLE 171 REST OF LATIN AMERICA: BREAST BIOPSY DEVICES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 191 TABLE 172 REST OF LATIN AMERICA: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 191 TABLE 173 REST OF LATIN AMERICA: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 192 TABLE 174 REST OF LATIN AMERICA: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 192 TABLE 175 MIDDLE EAST & AFRICA: KEY MACROINDICATORS 193 TABLE 176 MIDDLE EAST & AFRICA: BREAST BIOPSY DEVICES MARKET, BY REGION, 2023–2030 (USD MILLION) 193 TABLE 177 MIDDLE EAST & AFRICA: BREAST BIOPSY DEVICES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 194 TABLE 178 MIDDLE EAST & AFRICA: BREAST BIOPSY DEVICES MARKET, BY PROCEDURE, 2023–2030 (USD MILLION) 194 TABLE 179 MIDDLE EAST & AFRICA: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 195 TABLE 180 MIDDLE EAST & AFRICA: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 195 TABLE 181 MIDDLE EAST & AFRICA: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 196 TABLE 182 MIDDLE EAST & AFRICA: BREAST BIOPSY DEVICES MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 196 TABLE 183 MIDDLE EAST & AFRICA: BREAST BIOPSY DEVICES MARKET, BY END USER, 2023–2030 (USD MILLION) 197 TABLE 184 GCC COUNTRIES: BREAST BIOPSY DEVICES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 197 TABLE 185 GCC COUNTRIES: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 198 TABLE 186 GCC COUNTRIES: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 198 TABLE 187 GCC COUNTRIES: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 199 TABLE 188 REST OF MIDDLE EAST & AFRICA: BREAST BIOPSY DEVICES MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 200 TABLE 189 REST OF MIDDLE EAST & AFRICA: NEEDLE BREAST BIOPSY DEVICES MARKET, BY TYPE, 2023–2030 (USD MILLION) 200 TABLE 190 REST OF MIDDLE EAST & AFRICA: BREAST BIOPSY DEVICES MARKET FOR BIOPSY EQUIPMENT, BY TYPE, 2023–2030 (USD MILLION) 201 TABLE 191 REST OF MIDDLE EAST & AFRICA: BREAST BIOPSY DEVICES MARKET FOR GUIDANCE SYSTEMS, BY TYPE, 2023–2030 (USD MILLION) 201 TABLE 192 OVERVIEW OF STRATEGIES DEPLOYED BY KEY BREAST BIOPSY DEVICE MANUFACTURING COMPANIES 203 TABLE 193 BREAST BIOPSY DEVICES MARKET: DEGREE OF COMPETITION 206 TABLE 194 BREAST BIOPSY DEVICES MARKET: REGION FOOTPRINT 211 TABLE 195 BREAST BIOPSY DEVICES MARKET: PRODUCT FOOTPRINT 212 TABLE 196 BREAST BIOPSY DEVICES MARKET: PROCEDURE FOOTPRINT 213 TABLE 197 BREAST BIOPSY DEVICES MARKET: APPLICATION FOOTPRINT 214 TABLE 198 BREAST BIOPSY DEVICES MARKET: END USER FOOTPRINT 215 TABLE 199 BREAST BIOPSY DEVICES MARKET: DETAILED LIST OF KEY STARTUPS/SMES 218 TABLE 200 BREAST BIOPSY DEVICES MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS, BY REGION 218 TABLE 201 BREAST BIOPSY DEVICES MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS, BY PRODUCT 219 TABLE 202 BREAST BIOPSY DEVICES MARKET: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025 222 TABLE 203 BREAST BIOPSY DEVICES MARKET: DEALS, JANUARY 2021–MAY 2025 223 TABLE 204 HOLOGIC, INC. BUSINESS OVERVIEW 224 TABLE 205 HOLOGIC, INC.: PRODUCTS OFFERED 225 TABLE 206 HOLOGIC, INC.: DEALS, JANUARY 2021–MAY 2025 226 TABLE 207 DANAHER CORPORATION: COMPANY OVERVIEW 228 TABLE 208 DANAHER CORPORATION: PRODUCTS OFFERED 229 TABLE 209 DANAHER CORPORATION: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025 230 TABLE 210 DANAHER CORPORATION: DEALS, JANUARY 2021–MAY 2025 231 TABLE 211 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW 233 TABLE 212 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED 234 TABLE 213 ARGON MEDICAL: COMPANY OVERVIEW 236 TABLE 214 ARGON MEDICAL: PRODUCTS OFFERED 236 TABLE 215 ARGON MEDICAL: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025 237 TABLE 216 ARGON MEDICAL: DEALS, JANUARY 2021–MAY 2025 237 TABLE 217 QIAGEN: COMPANY OVERVIEW 239 TABLE 218 QIAGEN: PRODUCTS OFFERED 240 TABLE 219 QIAGEN: DEALS, JANUARY 2021–MAY 2025 241 TABLE 220 MERIT MEDICAL SYSTEMS: COMPANY OVERVIEW 242 TABLE 221 MERIT MEDICAL SYSTEMS: PRODUCTS OFFERED 243 TABLE 222 MERIT MEDICAL SYSTEMS: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025 244 TABLE 223 MERIT MEDICAL SYSTEMS: DEALS, JANUARY 2021–MAY 2025 245 TABLE 224 MENARINI SILICON BIOSYSTEMS SPA: COMPANY OVERVIEW 246 TABLE 225 MENARINI SILICON BIOSYSTEMS SPA: PRODUCTS OFFERED 246 TABLE 226 MENARINI SILICON BIOSYSTEMS SPA: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025 247 TABLE 227 MENARINI SILICON BIOSYSTEMS SPA: DEALS, JANUARY 2021–MAY 2025 247 TABLE 228 GUARDANT HEALTH, INC.: COMPANY OVERVIEW 248 TABLE 229 GUARDANT HEALTH, INC.: PRODUCTS OFFERED 249 TABLE 230 GUARDANT HEALTH, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025 250 TABLE 231 GUARDANT HEALTH, INC.: DEALS, JANUARY 2021–MAY 2025 250 TABLE 232 GUARDANT HEALTH, INC.: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2025 251 TABLE 233 NEOGENOMICS LABORATORIES, INC.: COMPANY OVERVIEW 252 TABLE 234 NEOGENOMICS LABORATORIES, INC.: PRODUCTS OFFERED 253 TABLE 235 NEOGENOMICS LABORATORIES, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025 253 TABLE 236 NEOGENOMICS LABORATORIES, INC.: DEALS, JANUARY 2021–MAY 2025 254 TABLE 237 STERYLAB S.R.L: COMPANY OVERVIEW 255 TABLE 238 STERYLAB S.R.L: PRODUCTS OFFERED 255 TABLE 239 BIOCEPT, INC.: COMPANY OVERVIEW 256 TABLE 240 BIOCEPT, INC.: PRODUCTS OFFERED 256 TABLE 241 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 258 TABLE 242 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED 259 TABLE 243 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2021–MAY 2025 260 TABLE 244 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 261 TABLE 245 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED 262 TABLE 246 EXACT SCIENCES CORPORATION: COMPANY OVERVIEW 263 TABLE 247 EXACT SCIENCES CORPORATION: PRODUCTS OFFERED 264 TABLE 248 EXACT SCIENCES CORPORATION: DEALS, JANUARY 2021–MAY 2025 265 TABLE 249 SYSMEX INOSTICS: COMPANY OVERVIEW 266 TABLE 250 SYSMEX INOSTICS: PRODUCTS OFFERED 267 TABLE 251 SYSMEX INOSTICS: DEALS, JANUARY 2021–MAY 2025 268 TABLE 252 THERMO FISHER SCIENTIFIC: COMPANY OVERVIEW 269 TABLE 253 THERMO FISHER SCIENTIFIC: PRODUCTS OFFERED 270 TABLE 254 THERMO FISHER SCIENTIFIC: DEALS, JANUARY 2021–MARCH 2024 271 TABLE 255 FUJIFILM HOLDINGS CORPORATION: COMPANY OVERVIEW 272 TABLE 256 FUJIFILM HOLDINGS CORPORATION: PRODUCTS OFFERED 273 TABLE 257 CARDIFF ONCOLOGY INC.: COMPANY OVERVIEW 274 TABLE 258 MYRIAD GENETICS, INC.: COMPANY OVERVIEW 275 TABLE 259 ILLUMINA, INC.: COMPANY OVERVIEW 276 TABLE 260 FLUXION BIOSCIENCES, INC.: COMPANY OVERVIEW 277 TABLE 261 INRAD, INC.: COMPANY OVERVIEW 278 TABLE 262 IZI MEDICAL PRODUCTS: COMPANY OVERVIEW 279 TABLE 263 REMINGTON MEDICAL INC.: COMPANY OVERVIEW 280 TABLE 264 CP MEDICAL: COMPANY OVERVIEW 281 FIGURE 1 BREAST BIOPSY DEVICES MARKET SEGMENTATION & REGIONAL SCOPE 27 FIGURE 2 BREAST BIOPSY DEVICES MARKET: RESEARCH DATA 31 FIGURE 3 BREAST BIOPSY DEVICES MARKET: RESEARCH DESIGN 32 FIGURE 4 BREAST BIOPSY DEVICES MARKET: KEY DATA FROM SECONDARY SOURCES 34 FIGURE 5 BREAST BIOPSY DEVICES MARKET: PRIMARY SOURCES 35 FIGURE 6 BREAST BIOPSY DEVICES MARKET: KEY INDUSTRY INSIGHTS 36 FIGURE 7 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION 36 FIGURE 8 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY- AND DEMAND-SIDE PARTICIPANTS 37 FIGURE 9 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 38 FIGURE 10 BREAST BIOPSY DEVICES MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH (REVENUE SHARE ANALYSIS) 39 FIGURE 11 BREAST BIOPSY DEVICES MARKET SIZE ESTIMATION: COMPANY REVENUE ESTIMATION 40 FIGURE 12 BREAST BIOPSY DEVICES MARKET: TOP-DOWN APPROACH 41 FIGURE 13 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS 42 FIGURE 14 BREAST BIOPSY DEVICES MARKET: DATA TRIANGULATION 43 FIGURE 15 BREAST BIOPSY DEVICES MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION) 46 FIGURE 16 BREAST BIOPSY DEVICES MARKET, BY PROCEDURE, 2025 VS. 2030 (USD MILLION) 47 FIGURE 17 BREAST BIOPSY PROCEDURE GROWTH [ BIOPSY PROCEDURES IN ‘000S VS FEMALES AGED 40 – 69 YEARS IN MILLIONS (2023) ] 47 FIGURE 18 BREAST BIOPSY DEVICES MARKET, BY APPLICATION, 2025 VS. 2030 (USD MILLION) 48 FIGURE 19 BREAST BIOPSY DEVICES MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 48 FIGURE 20 BREAST BIOPSY DEVICES MARKET: REGIONAL SNAPSHOT 49 FIGURE 21 GROWING INCIDENCE OF BREAST CANCER TO DRIVE MARKET 50 FIGURE 22 NORTH AMERICA TO ACCOUNT FOR LARGEST SHARE OF MARKET DURING FORECAST PERIOD 51 FIGURE 23 EARLY CANCER SCREENING SEGMENT ACCOUNTED FOR LARGEST MARKET SHARE IN 2024 52 FIGURE 24 CHINA TO REGISTER HIGHEST GROWTH RATE DURING FORECAST PERIOD 53 FIGURE 25 BREAST BIOPSY DEVICES MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 54 FIGURE 26 VALUE CHAIN ANALYSIS—MAXIMUM VALUE ADDED DURING MANUFACTURING PHASE 69 FIGURE 27 BREAST BIOPSY DEVICES MARKET: SUPPLY CHAIN ANALYSIS 70 FIGURE 28 BREAST BIOPSY DEVICES MARKET: ECOSYSTEM ANALYSIS 71 FIGURE 29 PATENT DETAILS FOR BREAST BIOPSY DEVICES (JANUARY 2013–MAY 2025) 76 FIGURE 30 BREAST BIOPSY DEVICES MARKET: PORTER’S FIVE FORCES ANALYSIS 77 FIGURE 31 AVERAGE SELLING PRICE TREND OF BREAST BIOPSY DEVICES, BY REGION, 2022–2024 (USD) 79 FIGURE 32 AVERAGE SELLING PRICE OF BREAST BIOPSY DEVICES, BY KEY PLAYER, 2024 (USD) 81 FIGURE 33 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF BREAST BIOPSY DEVICES, BY TOP THREE END USERS 84 FIGURE 34 KEY BUYING CRITERIA FOR TOP THREE END USERS OF BREAST BIOPSY DEVICES 85 FIGURE 35 BREAST BIOPSY DEVICES: INVESTMENT & FUNDING SCENARIO 90 FIGURE 36 NUMBER OF INVESTOR DEALS, BY KEY PLAYER, 2019–2023 90 FIGURE 37 VALUE OF INVESTOR DEALS, BY KEY PLAYER, 2018–2022 (USD MILLION) 91 FIGURE 38 NORTH AMERICA: BREAST BIOPSY DEVICES MARKET SNAPSHOT 133 FIGURE 39 ASIA PACIFIC: BREAST BIOPSY DEVICES MARKET SNAPSHOT 163 FIGURE 40 REVENUE ANALYSIS OF TOP 5 PLAYERS IN BREAST BIOPSY DEVICES MARKET, 2020–2024 205 FIGURE 41 MARKET SHARE ANALYSIS OF KEY PLAYERS IN BREAST BIOPSY DEVICES MARKET (2024) 205 FIGURE 42 BREAST BIOPSY DEVICES MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2024 209 FIGURE 43 BREAST BIOPSY DEVICES MARKET: COMPANY FOOTPRINT 210 FIGURE 44 BREAST BIOPSY DEVICES MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2024 217 FIGURE 45 EV/EBITDA OF KEY VENDORS 220 FIGURE 46 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS 220 FIGURE 47 BREAST BIOPSY DEVICES MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 221 FIGURE 48 HOLOGIC, INC.: COMPANY SNAPSHOT (2024) 225 FIGURE 49 DANAHER CORPORATION: COMPANY SNAPSHOT (2024) 229 FIGURE 50 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2024) 234 FIGURE 51 QIAGEN: COMPANY SNAPSHOT (2024) 240 FIGURE 52 MERIT MEDICAL SYSTEMS: COMPANY SNAPSHOT (2024) 243 FIGURE 53 GUARDANT HEALTH, INC.: COMPANY SNAPSHOT (2024) 249 FIGURE 54 NEOGENOMICS LABORATORIES, INC.: COMPANY SNAPSHOT (2023) 252 FIGURE 55 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2024) 259 FIGURE 56 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2024) 262 FIGURE 57 EXACT SCIENCES CORPORATION: COMPANY SNAPSHOT (2024) 264 FIGURE 58 SYSMEX INOSTICS: COMPANY SNAPSHOT (2024) 267 FIGURE 59 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2024) 270 FIGURE 60 FUJIFILM HOLDINGS CORPORATION: COMPANY SNAPSHOT (2024) 273

同分類最新報告(醫療器材)

量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理,提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們